New research published in the International Journal of Obesity now suggests that widely used GLP-1based anti-obesity medicines may offer a potential therapeutic approach even when this critical biological pathway is absent
These medications were initially created to treat type 2 diabetes and have been extensively researched for several decades
Angry patients spur new state watchdogs to bring down drug prices But one researcher, John Cawley, a professor of economics and public policy at Cornell University, and his colleagues found that while obesity basically doubles a persons annual health care costs, the savings associated with public insurance plans covering GLP-1s for just obesity treatment are dependent on the patients starting body mass index, or BMI
Real-world combination scenarios Understanding the research is one thing
This pigment is what gives melanocytic nevi a tan to dark brown color
In other words, the people who need appetite control the most are naturally getting the least of it
